Glasdegib

Drug Profile

Glasdegib

Alternative Names: Oral Hedgehog Inhibitor - Pfizer; PF-04449913; PF-4449913; Smo Inhibitor - Pfizer; Sonic Hedgehog pathway inhibitor (PF 4449913) - Pfizer

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Pfizer
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I/II Chronic myelomonocytic leukaemia
  • Phase I Haematological malignancies
  • No development reported Solid tumours

Most Recent Events

  • 03 Dec 2016 New safety and efficacy data from phase II trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-myeloid-leukaemia(Monotherapy, Second-line therapy or greater) in Italy (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies(Monotherapy, Second-line therapy or greater) in Italy (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top